Neurologic Presentations of AIDS

Neurologic Clinics

Volumn 28, Issue 1, 2010, Pages 253-275

  Singer, Elyse J ^a,b   Valdes Sueiras, Miguel ^a   Commins, Deborah ^c   Levine, Andrew ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b National Neurological AIDS Bank   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AIDS; Brain; HIV; Opportunistic infection

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; BACLOFEN; BOTULINUM TOXIN; CIDOFOVIR; CYTARABINE; DANTROLENE; DIDANOSINE; GANCICLOVIR; IMMUNOGLOBULIN; LAMOTRIGINE; MEMANTINE; METHIONINE; METHYLPHENIDATE; MINOCYCLINE; NERVE GROWTH FACTOR; NIMODIPINE; PEPTIDE T; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SELEGILINE; STAVUDINE; TIZANIDINE; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN LYMPHOMA; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; COGNITIVE DEFECT; CRYPTOCOCCAL MENINGITIS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG PENETRATION; ELECTROMYOGRAM; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LUMBAR PUNCTURE; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SKULL IRRADIATION; SPINAL CORD DISEASE; TOXOPLASMOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BRAIN; HIV-1; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 70449650501     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2009.09.018     Document Type: Review

References (191)

1. UNAIDS. Report on the global AIDS epidemic 2008 (2007), UNAIDS, Geneva
2. Patrick M.K., Johnston J.B., and Power C. Lentiviral neuropathogenesis: comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility. J Virol 76 (2002) 7923-7931
3. Wiley C.A., Schrier R.D., Nelson J.A., et al. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 83 (1986) 7089-7093
4. Kaul M., and Lipton S.A. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 4 (2006) 307-318
5. Letendre S., Marquie-Beck J., Capparelli E., et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65 (2008) 65-70
6. Clements J.E., Li M., Gama L., et al. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 11 (2005) 180-189
7. Brew B.J., Crowe S.M., Landay A., et al. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 4 (2009) 163-174
8. Huang S.T., Lee H.C., Liu K.H., et al. Acute human immunodeficiency virus infection. J Microbiol Immunol Infect 38 (2005) 65-68
9. Fox R., Eldred L.J., Fuchs E.J., et al. Clinical manifestations of acute infection with human immunodeficiency virus in a cohort of gay men. AIDS 1 (1987) 35-38
10. Resnick L., Berger J.R., Shapshak P., et al. Early penetration of the blood-brain-barrier by HIV. Neurology 38 (1988) 9-14
11. Tarasow E., Wiercinska-Drapalo A., Kubas B., et al. Cerebral MR spectroscopy in neurologically asymptomatic HIV-infected patients. Acta Radiol 44 (2003) 206-212
12. Krasner C.G., and Cohen S.H. Bilateral Bell's palsy and aseptic meningitis in a patient with acute human immunodeficiency virus seroconversion. West J Med 159 (1993) 604-605
13. Serrano P., Hernandez N., Arroyo J.A., et al. Bilateral Bell palsy and acute HIV type 1 infection: report of 2 cases and review. Clin Infect Dis 44 (2007) e57-e61
14. Hollander H., and Stringari S. Human immunodeficiency virus-associated meningitis. Clinical course and correlations. Am J Med 83 (1987) 813-816
15. Hollander H., and Levy J.A. Neurologic abnormalities and recovery of human immunodeficiency virus from cerebrospinal fluid. Ann Intern Med 106 (1987) 692-695
16. Wendel K.A., and McArthur J.C. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis 37 (2003) 1107-1111
17. Worthington M.G., and Ross J.J. Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. AIDS 17 (2003) 2145-2146
18. Antinori A., Arendt G., Becker J.T., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69 (2007) 1789-1799
19. Woods S.P., Moore D.J., Weber E., et al. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 19 (2009) 152-168
20. Reger M., Welsh R., Razani J., et al. A meta-analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc 8 (2002) 410-424
21. Tross S., Price R.W., Navia B., et al. Neuropsychological characterization of the AIDS dementia complex: a preliminary report. AIDS 2 (1988) 81-88
22. Delis D.C., Peavy G., Heaton R., et al. Do patients with HIV-associated minor cognitive/motor disorder exhibit a 'subcortical' memory profile? Evidence using the California verbal learning test. Assessment 2 (1995) 151-165
23. Pillon B., Deweer B., Michon A., et al. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases. Neurology 44 (1994) 1264-1270
24. Navia B.A., Cho E.S., Petito C.K., et al. The AIDS dementia complex: II. Neuropathology. Ann Neurol 19 (1986) 525-535
25. Tisch S., and Brew B. Parkinsonism in HIV-infected patients on highly active antiretroviral therapy. Neurology 73 (2009) 401-403
26. Castellon S.A., Hinkin C.H., and Myers H.F. Neuropsychiatric disturbance is associated with executive dysfunction in HIV-1 infection. J Int Neuropsychol Soc 6 (2000) 336-347
27. Cole M.A., Castellon S.A., Perkins A.C., et al. Relationship between psychiatric status and frontal-subcortical systems in HIV-infected individuals. J Int Neuropsychol Soc 13 (2007) 549-554
28. Ayuso Mateos J.L., Singh A.N., and Catalan J. Drug treatment of HIV associated neuropsychiatric syndromes. Neurologia 15 (2000) 164-171
29. Bing E.G., Burnam M.A., Longshore D., et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 58 (2001) 721-728
30. Lyketsos C.G., Schwartz J., Fishman M., et al. AIDS mania. J Neuropsychiatry Clin Neurosci 9 (1997) 277-279
31. Nakimuli-Mpungu E., Musisi S., Mpungu S.K., et al. Primary mania versus HIV-related secondary mania in Uganda. Am J Psychiatry 163 (2006) 1349-1354 [quiz 1480]
32. Portegies P., Enting R.H., de Gans J., et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS 7 (1993) 669-675
33. McArthur J.C., Hoover D.R., Bacellar H., et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43 (1993) 2245-2252
34. Ellis R.J., Moore D.J., Childers M.E., et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 59 (2002) 923-928
35. Stern Y., McDermott M.P., Albert S., et al. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 58 (2001) 473-479
36. Navia B.A., Jordan B.D., and Price R.W. The AIDS dementia complex: I. Clinical features. Ann Neurol 19 (1986) 517-524
37. Snider W.D., Simpson D.M., Nielsen S., et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 14 (1983) 403-418
38. McArthur J.C. HIV dementia: an evolving disease. J Neuroimmunol 157 (2004) 3-10
39. Brew B.J. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 18 Suppl 1 (2004) S75-S78
40. Ernst T., and Chang L. Effect of aging on brain metabolism in antiretroviral-naive HIV patients. AIDS 18 Suppl 1 (2004) S61-S67
41. Dore G.J., Correll P.K., Li Y., et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13 (1999) 1249-1253
42. Sevigny J.J., Albert S.M., McDermott M.P., et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63 (2004) 2084-2090
43. Cysique L.A., Brew B.J., Halman M., et al. Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr 39 (2005) 426-429
44. Descamps M., Hyare H., Stebbing J., et al. Magnetic resonance imaging and spectroscopy of the brain in HIV disease. J HIV Ther 13 (2008) 55-58
45. Paul R.H., Ernst T., Brickman A.M., et al. Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. J Int Neuropsychol Soc 14 (2008) 725-733
46. Paul R.H., Brickman A.M., Navia B., et al. Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. J Neuropsychiatry Clin Neurosci 17 (2005) 167-171
47. Chiang M.C., Dutton R.A., Hayashi K.M., et al. 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. Neuroimage 34 (2007) 44-60
48. Lentz M.R., Kim W.K., Lee V., et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 72 (2009) 1465-1472
49. Paul R.H., Yiannoutsos C.T., Miller E.N., et al. Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci 19 (2007) 283-292
50. Rottenberg D.A., Sidtis J.J., Strother S.C., et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 37 (1996) 1133-1141
51. Rottenberg D.A., Moeller J.R., Strother S.C., et al. The metabolic pathology of the AIDS dementia complex. Ann Neurol 22 (1987) 700-706
52. Schmitt F.A., Bigley J.W., McKinnis R., et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 319 (1988) 1573-1578
53. Sidtis J.J., Gatsonis C., Price R.W., et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 33 (1993) 343-349
54. Portegies P., Solod L., Cinque P., et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 11 (2004) 297-304
55. Sacktor N.C., Lyles R.H., Skolasky R.L., et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology 52 (1999) 1640-1647
56. Brodt H.R., Kamps B.S., Gute P., et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11 (1997) 1731-1738
57. Marra C.M., Zhao Y., Clifford D.B., et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23 (2009) 1359-1366
58. Tozzi V., Balestra P., Salvatori M.F., et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 52 (2009) 56-63
59. Uthman O.A., and Abdulmalik J.O. Adjunctive therapies for AIDS dementia complex. Cochrane Database Syst Rev 3 (2008) CD006496
60. Breitbart W., Rosenfeld B., Kaim M., et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 161 (2001) 411-420
61. Hinkin C.H., Castellon S.A., Hardy D.J., et al. Methylphenidate improves HIV-1-associated cognitive slowing. J Neuropsychiatry Clin Neurosci 13 (2001) 248-254
62. Petito C.K. Review of central nervous system pathology in human immunodeficiency virus infection. Ann Neurol 23 Suppl (1988) S54-S57
63. Dal Pan G.J., Glass J.D., and McArthur J.C. Clinicopathologic correlations of HIV-1-associated vacuolar myelopathy: an autopsy-based case-control study. Neurology 44 (1994) 2159-2164
64. Berger J.R., and Sabet A. Infectious myelopathies. Semin Neurol 22 (2002) 133-142
65. Di Rocco A., and Simpson D.M. AIDS-associated vacuolar myelopathy. AIDS Patient Care STDS 12 (1998) 457-461
66. Sartoretti-Schefer S., Blattler T., and Wichmann W. Spinal MRI in vacuolar myelopathy, and correlation with histopathological findings. Neuroradiology 39 (1997) 865-869
67. Chong J., Di Rocco A., Tagliati M., et al. MR findings in AIDS-associated myelopathy. AJNR Am J Neuroradiol 20 (1999) 1412-1416
68. Tagliati M., Di Rocco A., Danisi F., et al. The role of somatosensory evoked potentials in the diagnosis of AIDS-associated myelopathy. Neurology 54 (2000) 1477-1482
69. Petito C.K., Navia B.A., Cho E.S., et al. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med 312 (1985) 874-879
70. Petito C.K., Vecchio D., and Chen Y.T. HIV antigen and DNA in AIDS spinal cords correlate with macrophage infiltration but not with vacuolar myelopathy. J Neuropathol Exp Neurol 53 (1994) 86-94
71. Rosenblum M., Scheck A.C., Cronin K., et al. Dissociation of AIDS-related vacuolar myelopathy and productive HIV-1 infection of the spinal cord. Neurology 39 (1989) 892-896
72. Eilbott D.J., Peress N., Burger H., et al. Human immunodeficiency virus type 1 in spinal cords of acquired immunodeficiency syndrome patients with myelopathy: expression and replication in macrophages. Proc Natl Acad Sci U S A 86 (1989) 3337-3341
73. Geraci A., Di Rocco A., Liu M., et al. AIDS myelopathy is not associated with elevated HIV viral load in cerebrospinal fluid. Neurology 55 (2000) 440-442
74. Di Rocco A., Bottiglieri T., Werner P., et al. Abnormal cobalamin-dependent transmethylation in AIDS-associated myelopathy. Neurology 58 (2002) 730-735
75. Tan S.V., and Guiloff R.J. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. J Neurol Neurosurg Psychiatry 65 (1998) 23-28
76. Tan S.V., Guiloff R.J., Henderson D.C., et al. AIDS-associated vacuolar myelopathy and tumor necrosis factor-alpha (TNF alpha). J Neurol Sci 138 (1996) 134-144
77. Di Rocco A., Werner P., Bottiglieri T., et al. Treatment of AIDS-associated myelopathy with L-methionine: a placebo-controlled study. Neurology 63 (2004) 1270-1275
78. Bizaare M., Dawood H., and Moodley A. Vacuolar myelopathy: a case report of functional, clinical, and radiological improvement after highly active antiretroviral therapy. Int J Infect Dis 12 (2008) 442-444
79. Di Rocco A., and Tagliati M. Remission of HIV myelopathy after highly active antiretroviral therapy. Neurology 55 (2000) 456
80. Staudinger R., and Henry K. Remission of HIV myelopathy after highly active antiretroviral therapy. Neurology 54 (2000) 267-268
81. Rottnek M., Di Rocco A., Laudier D., et al. Axonal damage is a late component of vacuolar myelopathy. Neurology 58 (2002) 479-481
82. Verma S., Estanislao L., and Simpson D. HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs 19 (2005) 325-334
83. Letendre S.L., Ellis R.J., Everall I., et al. Neurologic complications of HIV disease and their treatment. Top HIV Med 17 (2009) 46-56
84. Lopez O.L., Becker J.T., Dew M.A., et al. Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. Eur J Neurol 11 (2004) 97-102
85. Lichtenstein K.A., Armon C., Baron A., et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 40 (2005) 148-157
86. Simpson D.M. Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 8 Suppl 2 (2002) 33-41
87. Cornblath D.R., and McArthur J.C. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 38 (1988) 794-796
88. Kennedy J.M., Hoke A., Zhu Y., et al. Peripheral neuropathy in lentivirus infection: evidence of inflammation and axonal injury. AIDS 18 (2004) 1241-1250
89. Zhu Y., Antony J., Liu S., et al. CD8+ lymphocyte-mediated injury of dorsal root ganglion neurons during lentivirus infection: CD154-dependent cell contact neurotoxicity. J Neurosci 26 (2006) 3396-3403
90. Herzberg U., and Sagen J. Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis. J Neuroimmunol 116 (2001) 29-39
91. de la Monte S.M., Gabuzda D.H., Ho D.D., et al. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol 23 (1988) 485-492
92. Evans S.R., Clifford D.B., Kitch D.W., et al. Simplification of the research diagnosis of HIV-associated sensory neuropathy. HIV Clin Trials 9 (2008) 434-439
93. McArthur J.C., Yiannoutsos C., Simpson D.M., et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54 (2000) 1080-1088
94. Evans S.R., Simpson D.M., Kitch D.W., et al. A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One 2 (2007) e551
95. Simpson D.M., McArthur J.C., Olney R., et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60 (2003) 1508-1514
96. Simpson D.M., Brown S., and Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70 (2008) 2305-2313
97. Abrams D.I., Jay C.A., Shade S.B., et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68 (2007) 515-521
98. Ellis R.J., Toperoff W., Vaida F., et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34 (2009) 672-680
99. Hahn K., Arendt G., Braun J.S., et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 251 (2004) 1260-1266
100. Kieburtz K., Simpson D., Yiannoutsos C., et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 51 (1998) 1682-1688
101. Shlay J.C., Chaloner K., Max M.B., et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 280 (1998) 1590-1595
102. Schifitto G., Yiannoutsos C.T., Simpson D.M., et al. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 12 (2006) 328-331
103. Simpson D.M., Dorfman D., Olney R.K., et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 47 (1996) 1254-1259
104. Moore R.D., Wong W.M., Keruly J.C., et al. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 14 (2000) 273-278
105. Verma A. Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst 6 (2001) 8-13
106. Arenas-Pinto A., Bhaskaran K., Dunn D., et al. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. Antivir Ther 13 (2008) 289-295
107. Lee H., Hanes J., and Johnson K.A. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42 (2003) 14711-14719
108. Peltier A.C., and Russell J.W. Recent advances in drug-induced neuropathies. Curr Opin Neurol 15 (2002) 633-638
109. Zhu Y., Antony J.M., Martinez J.A., et al. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain 130 (2007) 2011-2023
110. Canter J.A., Haas D.W., Kallianpur A.R., et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J 8 (2008) 71-77
111. Berger A.R., Arezzo J.C., Schaumburg H.H., et al. 2′,3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 43 (1993) 358-362
112. Hagberg L., Malmvall B.E., Svennerholm L., et al. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis 18 (1986) 591-592
113. de Castro G., Bastos P.G., Martinez R., et al. Episodes of Guillain-Barré syndrome associated with the acute phase of HIV-1 infection and with recurrence of viremia. Arq Neuropsiquiatr 64 (2006) 606-608
114. Teo E.C., Azwra A., Jones R.L., et al. Guillain-Barré syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection. J HIV Ther 12 (2007) 62-63
115. McLeod J.G. Electrophysiological studies in the Guillain-Barré syndrome. Ann Neurol 9 Suppl (1981) 20-27
116. Cornblath D.R. Treatment of the neuromuscular complications of human immunodeficiency virus infection. Ann Neurol 23 Suppl (1988) S88-S91
117. Bani-Sadr F., Neuville S., Crassard I., et al. Acute Guillain-Barré syndrome during the chronic phase of HIV infection and dramatic improvement under highly active antiretroviral therapy. AIDS 16 (2002) 1562
118. Sloan D.J., Nicolson A., Miller A.R., et al. Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report. J Med Case Reports 2 (2008) 370
119. Gorshtein A., and Levy Y. Intravenous immunoglobulin in therapy of peripheral neuropathy. Clin Rev Allergy Immunol 29 (2005) 271-279
120. Wulff E.A., Wang A.K., and Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 59 (2000) 1251-1260
121. Astrom K.E., Mancall E.L., and Richardson Jr. E.P. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81 (1958) 93-111
122. Padgett B.L., and Walker D.L. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 127 (1973) 467-470
123. Weber T., Trebst C., Frye S., et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 176 (1997) 250-254
124. Berger J.R., Pall L., Lanska D., et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 4 (1998) 59-68
125. Engsig F.N., Hansen A.B., Omland L.H., et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 199 (2009) 77-83
126. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
127. Whiteman M.L., Post M.J., Berger J.R., et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 187 (1993) 233-240
128. Du Pasquier R.A., and Koralnik I.J. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?. J Neurovirol 9 Suppl 1 (2003) 25-31
129. Hammarin A.L., Bogdanovic G., Svedhem V., et al. Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy. J Clin Microbiol 34 (1996) 2929-2932
130. Wang Y., Kirby J.E., and Qian Q. Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy. J Med Microbiol 58 (2009) 253-255
131. Royal III W., Dupont B., McGuire D., et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 9 (2003) 411-419
132. Enting R.H., and Portegies P. Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy. J Neurol 247 (2000) 134-138
133. Hall C.D., Dafni U., Simpson D., et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338 (1998) 1345-1351
134. Marra C.M., Rajicic N., Barker D.E., et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16 (2002) 1791-1797
135. Clifford D.B., Yiannoutsos C., Glicksman M., et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52 (1999) 623-625
136. Giudici B., Vaz B., Bossolasco S., et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30 (2000) 95-99
137. Levine A.J., Hinkin C.H., Ando K., et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol 30 7 (2008) 836-843
138. Griffiths P. Cytomegalovirus infection of the central nervous system. Herpes 11 Suppl 2 (2004) 95A-104A
139. Staras S.A., Dollard S.C., Radford K.W., et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43 (2006) 1143-1151
140. Embil J.A., Pereira L.H., MacNeil J.P., et al. Levels of cytomegalovirus seropositivity in homosexual and heterosexual men. Sex Transm Dis 15 (1988) 85-87
141. Skolnik P.R., Kosloff B.R., and Hirsch M.S. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis 157 (1988) 508-514
142. McCutchan J.A. Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis 21 Suppl 2 (1995) S196-S201
143. Arribas J.R., Storch G.A., Clifford D.B., et al. Cytomegalovirus encephalitis. Ann Intern Med 125 (1996) 577-587
144. Fiala M., Singer E.J., Graves M.C., et al. AIDS dementia complex complicated by cytomegalovirus encephalopathy. J Neurol 240 (1993) 223-231
145. Miller R.F., Fox J.D., Thomas P., et al. Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients. J Neurol Neurosurg Psychiatry 61 (1996) 456-460
146. So Y.T., and Olney R.K. Acute lumbosacral polyradiculopathy in acquired immunodeficiency syndrome: experience in 23 patients. Ann Neurol 35 (1994) 53-58
147. Cinque P., Bossolasco S., Bestetti A., et al. Molecular studies of cerebrospinal fluid in human immunodeficiency virus type 1-associated opportunistic central nervous system diseases-an update. J Neurovirol 8 Suppl 2 (2002) 122-128
148. de Gans J., Tiessens G., Portegies P., et al. Predominance of polymorphonuclear leukocytes in cerebrospinal fluid of AIDS patients with cytomegalovirus polyradiculomyelitis. J Acquir Immune Defic Syndr 3 (1990) 1155-1158
149. van Den Pol A.N., Mocarski E., Saederup N., et al. Cytomegalovirus cell tropism, replication, and gene transfer in brain. J Neurosci 19 (1999) 10948-10965
150. Wiley C.A., Schrier R.D., Denaro F.J., et al. Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. J Neuropathol Exp Neurol 45 (1986) 127-139
151. Chiou S.H., Liu J.H., Chen S.S., et al. Apoptosis of human retina and retinal pigment cells induced by human cytomegalovirus infection. Ophthalmic Res 34 (2002) 77-82
152. Odeberg J., Wolmer N., Falci S., et al. Human cytomegalovirus inhibits neuronal differentiation and induces apoptosis in human neural precursor cells. J Virol 80 (2006) 8929-8939
153. Morgello S., Cho E.S., Nielsen S., et al. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature. Hum Pathol 18 (1987) 289-297
154. Jabs D.A., Bolton S.G., Dunn J.P., et al. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 126 (1998) 817-822
155. Kaplan J.E., Benson C., Holmes K.H., et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58 (2009) 1-207 [quiz CE201-4]
156. Jarvis J.N., and Harrison T.S. HIV-associated cryptococcal meningitis. AIDS 21 (2007) 2119-2129
157. Polacheck I., Platt Y., and Aronovitch J. Catecholamines and virulence of Cryptococcus neoformans. Infect Immun 58 (1990) 2919-2922
158. Moosa M.Y., and Coovadia Y.M. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis 24 (1997) 131-134
159. Charlier C., Dromer F., Leveque C., et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One 3 (2008) e1950
160. Lortholary O., Poizat G., Zeller V., et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20 (2006) 2183-2191
161. Larsen R.A., Leal M.A., and Chan L.S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 113 (1990) 183-187
162. Graybill J.R., Sobel J., Saag M., et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 30 (2000) 47-54
163. Nascimento L.V., Stollar F., Tavares L.B., et al. Risk factors for toxoplasmic encephalitis in HIV-infected patients: a case-control study in Brazil. Ann Trop Med Parasitol 95 (2001) 587-593
164. Ho Y.C., Sun H.Y., Chen M.Y., et al. Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection. J Microbiol Immunol Infect 41 (2008) 386-392
165. Luft B.J., and Remington J.S. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 15 (1992) 211-222
166. Bousson V., Brunereau L., Meyohas M., et al. [Brain imaging in AIDS]. J Radiol 80 (1999) 99-107 [in French]
167. Bhagavati S., and Choi J. Frequent hemorrhagic lesions in cerebral toxoplasmosis in AIDS patients. J Neuroimaging 19 (2009) 169-173
168. Ruiz A., Ganz W.I., Post M.J., et al. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. AJNR Am J Neuroradiol 15 (1994) 1885-1894
169. Pierce M.A., Johnson M.D., Maciunas R.J., et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 123 (1995) 594-598
170. Miro J.M., Lopez J.C., Podzamczer D., et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis 43 (2006) 79-89
171. MacMahon E.M., Glass J.D., Hayward S.D., et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338 (1991) 969-973
172. Birx D.L., Redfield R.R., and Tosato G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med 314 (1986) 874-879
173. Petito C.K., Cho E.S., Lemann W., et al. Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 45 (1986) 635-646
174. Levy R.M., Bredesen D.E., and Rosenblum M.L. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 62 (1985) 475-495
175. Wolf T., Brodt H.R., Fichtlscherer S., et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 46 (2005) 207-215
176. Skiest D.J., and Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 17 (2003) 1787-1793
177. Bossolasco S., Cinque P., Ponzoni M., et al. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J Neurovirol 8 (2002) 432-438
178. Fan H., Kim S.C., Chima C.O., et al. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 75 (2005) 59-69
179. Gerstner E., and Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther 7 (2007) 689-700
180. Bossolasco S., Falk K.I., Ponzoni M., et al. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin Infect Dis 42 (2006) e21-e25
181. Correa D.D., DeAngelis L.M., Shi W., et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62 (2004) 548-555
182. Harder H., Holtel H., Bromberg J.E., et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62 (2004) 544-547
183. Riedel D.J., Pardo C.A., McArthur J., et al. Therapy insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol 2 (2006) 557-565
184. Vendrely A., Bienvenu B., Gasnault J., et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 109 (2005) 449-455
185. York J., Bodi I., Reeves I., et al. Raised intracranial pressure complicating cryptococcal meningitis: immune reconstitution inflammatory syndrome or recurrent cryptococcal disease?. J Infect 51 (2005) 165-171
186. Miller R.F., Isaacson P.G., Hall-Craggs M., et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol 108 (2004) 17-23
187. Venkataramana A., Pardo C.A., McArthur J.C., et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 67 (2006) 383-388
188. Langford T.D., Letendre S.L., Marcotte T.D., et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16 (2002) 1019-1029
189. Pfeffer G., Prout A., Hooge J., et al. Biopsy-proven immune reconstitution syndrome in a patient with AIDS and cerebral toxoplasmosis. Neurology 73 (2009) 321-322
190. Shelburne S.A., Visnegarwala F., Darcourt J., et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19 (2005) 399-406
191. Robertson J., Meier M., Wall J., et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 42 (2006) 1639-1646